Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and聽Federal Court in Delaware
Ceribell (Nasdaq: CBLL) has filed patent infringement complaints against Natus Medical Incorporated with both the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware. The complaints allege that Natus is infringing on six patents related to Ceribell's EEG headband and electrode design technology.
The company is seeking an exclusion order from USITC to prevent the importation of infringing Natus products into the United States. CEO Jane Chao emphasized Ceribell's significant investments in point-of-care EEG technology and commitment to protecting their intellectual property to continue delivering innovative healthcare solutions.
Ceribell (Nasdaq: CBLL) ha presentato denunce per violazione di brevetto contro Natus Medical Incorporated sia presso la U.S. International Trade Commission (USITC) che presso il Tribunale Distrettuale degli Stati Uniti nel Delaware. Le denunce sostengono che Natus stia violando sei brevetti relativi alla tecnologia del casco EEG e degli elettrodi di Ceribell.
L'azienda sta richiedendo un ordine di esclusione dall'USITC per impedire l'importazione negli Stati Uniti dei prodotti Natus che violano i brevetti. La CEO Jane Chao ha sottolineato i significativi investimenti di Ceribell nella tecnologia EEG point-of-care e l'impegno a proteggere la propriet脿 intellettuale per continuare a offrire soluzioni sanitarie innovative.
Ceribell (Nasdaq: CBLL) ha presentado denuncias por infracci贸n de patentes contra Natus Medical Incorporated ante la Comisi贸n Internacional de Comercio de EE. UU. (USITC) y el Tribunal de Distrito de EE. UU. en Delaware. Las denuncias alegan que Natus est谩 infringiendo seis patentes relacionadas con la tecnolog铆a del casco EEG y electrodos de Ceribell.
La empresa busca una orden de exclusi贸n de la USITC para impedir la importaci贸n de productos de Natus que infringen las patentes en Estados Unidos. La CEO Jane Chao destac贸 las importantes inversiones de Ceribell en tecnolog铆a EEG punto de atenci贸n y su compromiso para proteger su propiedad intelectual y continuar ofreciendo soluciones innovadoras en salud.
Ceribell (雮橃姢雼�: CBLL)鞚赌 Natus Medical Incorporated毳� 靸侂寑搿� 氙戈淡 甑牅氍挫棴鞙勳洂須�(USITC)鞕� 雿鸽澕鞗柎 鞐半癌歆�氚╇矔鞗愳棎 韸鬼棃 旃暣 靻岇啞鞚� 鞝滉赴頄堨姷雼堧嫟. 靻岇啞鞚赌 Natus臧� Ceribell鞚� EEG 項る摐氚措摐 氚� 鞝勱饭 靹り硠 旮办垹瓿� 甏�霠悳 鞐劘 臧滌潣 韸鬼棃毳� 旃暣頄堧嫟瓿� 欤检灔頃╇媹雼�.
須岇偓電� USITC鞐� 旃暣 鞝滍拡鞚� 氙戈淡 靾橃瀰鞚� 旮堨頃橂姅 氚办牅 氇呺牴鞚� 鞖旍箔頃橁碃 鞛堨姷雼堧嫟. CEO 鞝滌澑 彀槫電� Ceribell鞚� 順勳灔 EEG 旮办垹鞐� 靸侂嫻頃� 韴瀽毳� 頃挫檾鞙茧┌ 歆�鞝� 鞛偘甓� 氤错樃鞐� 鞝勲厫頃橃棳 順侅嫚鞝侅澑 鞚橂 靻旊（靺橃潉 歆�靻� 鞝滉车頃橁矤雼る姅 鞚橃毳� 臧曥“頄堨姷雼堧嫟.
Ceribell (Nasdaq : CBLL) a d茅pos茅 des plaintes pour violation de brevet contre Natus Medical Incorporated aupr猫s de la Commission internationale du commerce des 脡tats-Unis (USITC) et du tribunal de district des 脡tats-Unis dans le Delaware. Les plaintes all猫guent que Natus enfreint six brevets li茅s 脿 la technologie du bandeau EEG et des 茅lectrodes de Ceribell.
L'entreprise cherche 脿 obtenir une ordonnance d'exclusion de l'USITC pour emp锚cher l'importation aux 脡tats-Unis des produits Natus enfreignant les brevets. La PDG Jane Chao a soulign茅 les investissements importants de Ceribell dans la technologie EEG au point de soin et son engagement 脿 prot茅ger sa propri茅t茅 intellectuelle afin de continuer 脿 fournir des solutions de sant茅 innovantes.
Ceribell (Nasdaq: CBLL) hat Patentverletzungsklagen gegen Natus Medical Incorporated sowohl bei der US International Trade Commission (USITC) als auch beim US-Bezirksgericht in Delaware eingereicht. Die Klagen behaupten, dass Natus sechs Patente verletzt, die mit der EEG-Stirnband- und Elektroden-Designtechnologie von Ceribell zusammenh盲ngen.
Das Unternehmen strebt eine Ausschlussverf眉gung der USITC an, um die Einfuhr der verletzenden Natus-Produkte in die USA zu verhindern. CEO Jane Chao betonte die bedeutenden Investitionen von Ceribell in Point-of-Care-EEG-Technologie und das Engagement zum Schutz ihres geistigen Eigentums, um weiterhin innovative Gesundheitsl枚sungen anzubieten.
- Legal action demonstrates strong commitment to protecting valuable intellectual property assets
- Company shows confidence in patent portfolio strength with dual-front legal strategy
- Potential exclusion order could strengthen market position in EEG technology sector
- Legal proceedings may result in significant costs and resource allocation
- Uncertain timeline and outcome of patent litigation could impact business operations
- Risk of counter-litigation or challenges to patent validity
Insights
Ceribell's patent litigation against Natus could significantly impact both companies' market positions in the EEG technology sector.
Ceribell has initiated a two-pronged legal strategy against Natus Medical, filing complaints with both the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware. This approach demonstrates a robust enforcement stance, as the company alleges infringement of six patents related to its EEG headband and electrode design technology.
The USITC complaint is particularly significant, as Ceribell is seeking an exclusion order that would bar importation of allegedly infringing Natus products into the United States. Such orders can effectively eliminate a competitor from the U.S. market until the dispute is resolved or the products are redesigned to avoid infringement.
This litigation appears to focus on core technology in the point-of-care EEG space, where Ceribell has positioned itself as an innovator. The company's CEO explicitly mentions their commitment to protecting intellectual property to ensure continued development of
Patent litigation in medical technology often leads to one of several outcomes: settlement with licensing agreements, court-mandated royalties, product redesigns to avoid infringement, or market exclusion. The timeline for resolution could extend 18-36 months, creating uncertainty for both companies. For Ceribell, this represents a strategic assertion of its IP portfolio against a competitor, while potentially creating significant business challenges for Natus in the neurological monitoring space.
Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology
SUNNYVALE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (鈥淐eribell鈥�), a leading medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that it filed complaints against Natus Medical Incorporated and related subsidiaries (鈥淣atus鈥�), alleging patent infringement and unfair competition. A complaint was filed with the U.S. International Trade Commission (USITC), an independent, non-partisan agency that investigates and makes determinations in proceedings involving imports claimed to violate U.S. intellectual property rights.聽 Ceribell has requested that the USITC investigate its claims and issue an exclusion order to bar the importation of any infringing Natus products into the United States.聽
Ceribell also filed a with the U.S. District Court in Delaware asserting infringement of the same patents.
Ceribell initiated litigation because it believes Natus is infringing six of its patents related to important features of its EEG headband and electrode design.
鈥淔rom clinical research to continuous product advancements, Ceribell has made significant investments in point-of-care EEG technology,鈥� said Jane Chao, Ph.D., co-founder and CEO of Ceribell. 鈥淐eribell deeply values the innovations we bring to the healthcare community and is committed to fair competition. We will vigorously protect our intellectual property against infringement so that we can continue to deliver leading-edge products to healthcare professionals and their patients.鈥�
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our business plans, strategies, goals, prospects, assessments, beliefs, and expectations for our products, and other statements that are not statements of historical fact. Given their forward-looking nature, these statements involve substantial risks, uncertainties, and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渃ould,鈥� 鈥渓ikely,鈥� 鈥渙ngoing,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥減roject,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渂elieve,鈥� 鈥渁ssume,鈥� 鈥渢arget,鈥� 鈥渇orecast,鈥� 鈥済uidance,鈥� 鈥済oal,鈥� 鈥渙bjective,鈥� 鈥渁im,鈥� 鈥渟eek,鈥� 鈥減otential,鈥� 鈥渉ope,鈥� and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are risks related to the following: the macroeconomic and geopolitical environment, including the potential imposition of new or higher tariffs; our limited operating history and history of net losses; our ability to successfully achieve substantial market acceptance and adoption of our products; our ability to successfully address competitive pressures including legal actions; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; the manufacturing of a substantial number of our product components and their assembly in China or other countries; product defects or complaints and related liability; the complexity, timing, expense, and outcomes of clinical studies; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading 鈥淩isk Factors鈥� in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission (鈥淪EC鈥�). These filings, when made, are available on the Investor Relations section of our website at https://investors.ceribell.com and on the SEC鈥檚 website at https://sec.gov. We assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments.
About CeriBell, Inc.
Ceribell (Nasdaq: CBLL) is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Media Contact
Corrie Rose
FAQ
What legal action has Ceribell (CBLL) taken against Natus Medical in July 2025?
How many Ceribell patents are involved in the Natus Medical lawsuit?
What is Ceribell seeking from the USITC against Natus Medical?
Who is the CEO of Ceribell leading the patent infringement case?
What technology is at the center of Ceribell's patent dispute with Natus?
